Immunotherapy using autologous T cells has emerged to be a powerful treatment option for
patients with metastatic melanoma. These include the adoptive transfer of autologous tumor-…

T cell–mediated immunotherapies are promising cancer treatments. However, most patients
still fail to respond to these therapies. The molecular determinants of immune resistance are …

… Both programs were more pronounced in the post-treatment malignant cells and robustly
classified malignant cells as untreated or post treatment (AUC = 0.83 and 0.81 for cross-…

BACKGROUND. T cells expressing antigen-specific chimeric antigen receptors (CARs) improve
outcomes for CD19-expressing B cell malignancies. We evaluated a human application …

Adoptive immunotherapy retargeting T cells to CD19 via a chimeric antigen receptor (CAR)
is an investigational treatment capable of inducing complete tumor regression of B-cell …

Background: The Rnd proteins Rnd1, Rnd2, and Rnd3 (RhoE) comprise a unique branch of
Rho-family G-proteins that lack intrinsic GTPase activity and consequently remain …

Immune-profiling is becoming an important tool to identify predictive markers for the response
to immunotherapy. Our goal was to validate multiplex immunofluorescence (mIF) panels to …

The Rho GDP dissociation inhibitor (RhoGDI) regulates the activation—inactivation cycle of
Rho small GTPases, such as Cdc42 and RhoA, by extracting them from the membrane. To …

In addition to new tumour antigens, new prognostic and diagnostic markers are needed for
common cancers. In this study, we report the expression of Dickkopf-1 (DKK1) in multiple …

Genomic intratumor heterogeneity (ITH) may be associated with postsurgical relapse of
localized lung adenocarcinomas. Recently, mutations, through generation of neoantigens, were …